Below are current clinical trials.3 studies in Polycythemia vera
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points.
The current study is a minimal risk study that involves abstraction of clinical and laboratory information from patients with myeloid disorders with the intent to accurately define the natural history of a specific disease. The information includes survival, cause of death, disease complications, treatment, and other issues.
The purpose of this study is to assess the safety and drug/body interactions of TGR-1202 given together with ruxolitinib in patients who have myelodysplasia/myeloproliferative neoplasms, polycythemia vera, or myelofibrosis.
Feb. 08, 2017
- Tefferi A. Diagnostic approach to the patient with polycythemia. http://www.uptodate.com/home. Accessed Nov. 16, 2016.
- Polycythemia vera. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/poly/. Accessed Nov. 16, 2016.
- Tefferi A. Prognosis and treatment of polycythemia vera. http://www.uptodate.com/home. Accessed Nov. 16, 2016.
- Polycythemia vera facts. Leukemia & Lymphoma Society. https://www.lls.org/llssearch?search-terms=polycythemia+vera&search_language=en. Accessed Nov. 16, 2016.
- Mesa RA, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology. 2013;31:1285.
- Brian JC, et al. Overcoming treatment challenges in myelofibrosis and polycythemia vera: The role of ruxolitinib. Cancer Chemotherapy and Pharmacology. 2016;77:1125.
- Geyer H, et al. Symptomatic profiles of patients with polycythemia vera: Implications of inadequately controlled disease. Journal of Clinical Oncology. 2016;34:151.
- Polycythemia vera. Merck Manual Professional Version. http://www.merckmanuals.com/professional/hematology-and-oncology/myeloproliferative-disorders/polycythemia-vera. Accessed Nov. 16, 2016.